1B20 PCSK9 antagonists
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
Merck Sharpe & Dohme Corp.
A C C A A C A C C C C
A61P C07K C07K A61P A61K C12N A61P C07K C07K C07K C07K
inventional additional additional inventional additional inventional inventional additional additional additional inventional
Pingyu Holly A. Kevin Denise K. Shilpa Heidi Laurence B. Ayesha Feng Sonia M. Yan Rose M. Henryk Peizhi (Peter) Dana D. Timothy Jeffrey T. Jon H. Joseph C.
Zhong Hammond Wang Nawrocki Pandit Pixley Peterson Sitlani Dong Gregory Li Cubbon Mach Luo Wood McCabe Blue Condra Santoro